Fc?RIIb expression in early stage chronic lymphocytic leukemia
Por:
Bosch R., Mora A., Vicente E.P., Ferrer G., Jansà S., Damle R., Gorlatov S., Rai K., Montserrat E., Nomdedeu J., Pratcorona M., Blanco L., Saavedra S., Garrido A., Esquirol A., Garcia I., Granell M., Martino R., Delgado J., Sierra J., Chiorazzi N., Moreno C.
Publicada:
1 ene 2017
Resumen:
In normal B-cells, B-cell antigen receptor (BCR) signaling can be negatively regulated by the low-affinity receptor Fc?RIIb (CD32b). To better understand the role of Fc?RIIb in chronic lymphocytic leukemia (CLL), we correlated its expression on 155 samples from newly-diagnosed Binet A patients with clinical characteristics and outcome. Fc?RIIb expression was similar in normal B-cells and leukemic cells, this being heterogenous among patients and within CLL clones. Fc?RIIb expression did not correlate with well known prognostic markers [disease stage, serum beta-2 microglobulin (B2M), IGHV mutational status, expression of ZAP-70 and CD38, and cytogenetics] except for a weak concordance with CD49d. Moreover, patients with low Fc?RIIb expression (69/155, 44.5%) required therapy earlier than those with high Fc?RIIb expression (86/155, 55.5%) (median 151.4 months vs. not reached; p=.071). These results encourage further investigation on the role of Fc?RIIb in CLL biology and prognostic significance in larger series of patients. © 2017 Informa UK Limited, trading as Taylor & Francis Group.
Filiaciones:
Bosch R.:
Laboratory of Oncology/Hematology and Transplantation, Institute of Biomedical Research, IIB Sant Pau, Barcelona, Spain
Department of Hematology, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain
Mora A.:
Laboratory of Oncology/Hematology and Transplantation, Institute of Biomedical Research, IIB Sant Pau, Barcelona, Spain
Department of Hematology, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain
Vicente E.P.:
Laboratory of Oncology/Hematology and Transplantation, Institute of Biomedical Research, IIB Sant Pau, Barcelona, Spain
Department of Hematology, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain
Ferrer G.:
Karches Centre for Chronic Lymphocytic Leukemia Research, The Feinstein Institute for Medical Research, Manhasset, NY, United States
Jansà S.:
Department of Human Anatomy and Embryology, University of Barcelona, Barcelona, Spain
Damle R.:
Karches Centre for Chronic Lymphocytic Leukemia Research, The Feinstein Institute for Medical Research, Manhasset, NY, United States
Gorlatov S.:
MacroGenics, Inc, Rockville, MD, United States
Rai K.:
Haematology/Oncology, Oncology LIJ Medical Centre, Lake Success, NY, United States
Montserrat E.:
Department of Hematology, Institute of Hematology and Oncology, Hospital Clínic, IDIBAPS, Barcelona, Spain
Nomdedeu J.:
Laboratory of Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Pratcorona M.:
Laboratory of Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Blanco L.:
Laboratory of Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Saavedra S.:
Department of Hematology, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain
Garrido A.:
Department of Hematology, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain
Esquirol A.:
Department of Hematology, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain
Garcia I.:
Department of Hematology, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain
Granell M.:
Department of Hematology, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain
Martino R.:
Department of Hematology, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain
Delgado J.:
Department of Hematology, Institute of Hematology and Oncology, Hospital Clínic, IDIBAPS, Barcelona, Spain
Sierra J.:
Laboratory of Oncology/Hematology and Transplantation, Institute of Biomedical Research, IIB Sant Pau, Barcelona, Spain
Department of Hematology, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain
Chiorazzi N.:
Karches Centre for Chronic Lymphocytic Leukemia Research, The Feinstein Institute for Medical Research, Manhasset, NY, United States
Moreno C.:
Laboratory of Oncology/Hematology and Transplantation, Institute of Biomedical Research, IIB Sant Pau, Barcelona, Spain
Department of Hematology, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain
|